{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-022062","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.330583+00:00","generated_at":"2026-06-24T00:51:45.390822+00:00","sec_items":["1.01","2.02","2.03","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Celcuity expands debt to $75M, Q2 net loss $10M, gedatolisib gets Breakthrough Therapy","bullets":["Debt facility amended to up to $75M ($50M increase); $15M drawn, $20M due on private placement close; other tranches tied to clinical milestones.","Q2 2022 net loss $10.0M ($0.67 loss per share) vs $14.0M ($1.11) in Q2 2021; non-GAAP adjusted loss $8.3M ($0.55).","FDA granted Breakthrough Therapy designation in July for gedatolisib in HR+/HER2- metastatic breast cancer.","Private placement of $100M equity signed May 2022; closing expected after first patient dosed in VIKTORIA-1.","VIKTORIA-1 Phase 3 trial on track to dose first patient shortly; FACT-1/2 interim data expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-022062","json":"https://secwatch.observer/filing/0001493152-22-022062.json","markdown":"https://secwatch.observer/filing/0001493152-22-022062.md","text":"https://secwatch.observer/filing/0001493152-22-022062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/0001493152-22-022062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:51:45.390822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}